Sling has secured $123 million in funding to advance its experimental treatment for thyroid eye disease, positioning it as a potential oral alternative to existing injectable therapies like Amgen’s Tepezza and Viridian’s Lumvoa. This significant investment underscores the growing interest in innovative solutions for this debilitating condition, which affects patients’ quality of life and often requires long-term management.
A confirmatory late-stage study is now underway, which will assess the efficacy and safety of Sling’s candidate, linsitinib. If successful, this could not only provide a more convenient treatment option for patients but also reshape the competitive landscape within the thyroid eye disease market. As the demand for oral therapies increases, Sling’s initiative may attract further attention from regulatory bodies and investors alike, highlighting the ongoing evolution in treatment paradigms within the pharmaceutical industry.
Use the database as your supply chain compass →
